Business
Mesoblast stumbles as FDA demands more evidence of drug effectiveness – Sydney Morning Herald
The listed biotech’s push to get its flagship product approved in the US has suffered a setback, as the US regulator asks for more evidence of its effectiveness…
The biotech, valued at $1.9 billion, has been striving for a decade to get remestemcel-L approved in the US market. It is also trialling the same product for treatment of coronavirus, in cases where patients are experiencing severe respiratory distress.
The prospect of the coronavirus treatment has sent shares rallying in recent months. In April, Mesoblast shares were sitting at $1.46 but were at $5.08 before going into the trading halt this week.
Chief executive Silviu Itescu said he believed…
-
Noosa News23 hours agoLaidley e-scooter death: Tragic new details after Summah Richards killed in freak accident
-
General23 hours agoMinjee Lee rallies after third-round meltdown to share fifth place at LA Championship
-
General17 hours agoUkraine says Russia has ramped up attacks despite ‘Easter truce’
-
General22 hours agoEaster drowning toll in NSW rises after fisherman swept off rocks in Sydney’s south